Rituximab monotherapy for splenic marginal zone lymphoma

Haematologica

Volumn 90, Issue 6, 2005, Pages 856-858

  Bennett, Michael ^a   Sharma, Kumud ^b   Yegena, Shaiy ^c   Gavish, Israel ^a   Dave, Harish P ^b   Schechter, Geraldine P ^b  

^a HAEMEK MEDICAL CENTER   (Israel)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c Poriya Hospital   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CD103 ANTIGEN; CD19 ANTIGEN; CD20 ANTIBODY; CD20 ANTIGEN; CD22 ANTIGEN; CD23 ANTIGEN; CD5 ANTIGEN; CHIMERIC ANTIBODY; CHLORAMBUCIL; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLIN D1; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; INTERLEUKIN 2 RECEPTOR ALPHA; LEUKOSIALIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BLOOD CELL COUNT; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; LYMPHOMA; MALE; OUTCOMES RESEARCH; PATIENT SELECTION; PLEURA EFFUSION; RETROSPECTIVE STUDY; SPLEEN SIZE; SPLENECTOMY; SPLENIC MARGINAL ZONE LYMPHOMA; SPLENOMEGALY; SURVIVAL RATE; THROMBOCYTOPENIA; TUMOR LYSIS SYNDROME;

ADOLESCENT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; FEMALE; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; PLEURAL EFFUSION; RECURRENCE; RETROSPECTIVE STUDIES; SPLEEN;

EID: 21244453077     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organisation classification of tumours. Pathology and Genetics of Tumours of Haemopietic and Lymphoid Tissues. Lyon. IARC Press; 2001.
2. Catovsky D, Matutes E. Splenic lymphoma with circulating villous lymphocytes/splenic marginal-zone lymphoma. Semin Hematol 1999;36:148-54.
3. Jennings CD, Foon KA. Recent advances in flow cytometry: application to the diagnosis of hematologic malignancy. Blood 1997;90:2863-92.
4. Troussard X, Valensi F, Duchayne E, Garand R, Felman P, Tulliez M, et al. Splenic lymphoma with villous lymphocytes: clinical presentation, biology and prognostic factors in a series of 100 patients. Br J Haematol 1996;93:731-6.
5. Parry-Jones N, Matutes E, Gruszka-Westwood AM, Swansbury GJ, Wotherspoon AC, Catovsky, D. Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patients. Br J Haematol 2003;120:759-64.
6. Thomas DA, O'Brian S, Cortes J, Faderl S, Fayad L, Garcia-Manero G, et al. Treatment of splenic lymphoma with villous lymphocytes (SLVL) and marginal zone lymphomas (MZL) with single agent rituximab. Blood 2001; 98(suppl):134a (Abstract#563).
7. Arcaini L, Orlandi E, Scotti M, Brusamolino E, Passamonti F, Burcheri S, et al. Combination of rituximab, cyclophosphamide, and vincristine induces complete hematologic remission of splenic marginal zone lymphoma. Clin Lymphoma 2004;4:250-2.